Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in alzheimer disease

Randall (Randy) Woltjer, Kevin Duerson, Joseph M. Fullmer, Paramita Mookherjee, Allison M. Ryan, Thomas J. Montine, Jeffrey Kaye, Joseph Quinn, Lisa Silbert, Deniz Erten-Lyons, James B. Leverenz, Thomas D. Bird, David V. Pow, Kohichi Tanaka, G. Stennis Watson, David G. Cook

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Alzheimer disease (AD) is characterized by deposition of amyloid-β, tau, and other specific proteins that accumulate in the brain in detergent-insoluble complexes. Alzheimer disease also involves glutamatergic neurotransmitter system disturbances. Excitatory amino acid transporter 2 (EAAT2) is the dominant glutamate transporter in cerebral cortex and hippocampus. We investigated whether accumulation of detergent-insoluble EAAT2 is related to cognitive impairment and neuropathologic changes in AD by quantifying detergent-insoluble EAAT2 levels in hippocampus and frontal cortex of cognitively normal patients, patients with clinical dementia rating of 0.5 (mildly impaired), and AD patients. Parkinson disease patients served as neurodegenerative disease controls. We found that Triton X-100-insoluble EAAT2 levels were significantly increased in patients withAD compared with controls, whereas Triton X-100-insoluble EAAT2 levels inpatients with clinical dementia rating of 0.5 were intermediately elevatedbetween control and AD subjects. Detergentinsolubility of presenilin-1, a structurally similar protein, did not differ among the groups, thus arguing that EAAT2 detergent insolubility was not causedby nonspecific cellular injury. These findings demonstrate that detergent-insoluble EAAT2 accumulation is a progressive biochemical lesion that correlates with cognitive impairment and neuropathologic changes in AD. These findings lend further support to the idea that dysregulationof the glutamatergic system may play a significant role in AD pathogenesis.

Original languageEnglish (US)
Pages (from-to)667-676
Number of pages10
JournalJournal of Neuropathology and Experimental Neurology
Volume69
Issue number7
DOIs
StatePublished - Jul 2010

Fingerprint

Excitatory Amino Acid Transporter 2
Detergents
Alzheimer Disease
Octoxynol
Dementia
Hippocampus
Presenilin-1
Amino Acid Transport System X-AG
Frontal Lobe
Amyloid
Neurodegenerative Diseases
Cerebral Cortex
Neurotransmitter Agents
Parkinson Disease
Inpatients
Proteins

Keywords

  • Alzheimer disease
  • EAAT2
  • Excitotoxicity
  • Glutamate
  • Mild cognitive impairment
  • Oxidative stress
  • Protein aggregation
  • SLC1A2

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in alzheimer disease. / Woltjer, Randall (Randy); Duerson, Kevin; Fullmer, Joseph M.; Mookherjee, Paramita; Ryan, Allison M.; Montine, Thomas J.; Kaye, Jeffrey; Quinn, Joseph; Silbert, Lisa; Erten-Lyons, Deniz; Leverenz, James B.; Bird, Thomas D.; Pow, David V.; Tanaka, Kohichi; Watson, G. Stennis; Cook, David G.

In: Journal of Neuropathology and Experimental Neurology, Vol. 69, No. 7, 07.2010, p. 667-676.

Research output: Contribution to journalArticle

Woltjer, RR, Duerson, K, Fullmer, JM, Mookherjee, P, Ryan, AM, Montine, TJ, Kaye, J, Quinn, J, Silbert, L, Erten-Lyons, D, Leverenz, JB, Bird, TD, Pow, DV, Tanaka, K, Watson, GS & Cook, DG 2010, 'Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in alzheimer disease', Journal of Neuropathology and Experimental Neurology, vol. 69, no. 7, pp. 667-676. https://doi.org/10.1097/NEN.0b013e3181e24adb
Woltjer, Randall (Randy) ; Duerson, Kevin ; Fullmer, Joseph M. ; Mookherjee, Paramita ; Ryan, Allison M. ; Montine, Thomas J. ; Kaye, Jeffrey ; Quinn, Joseph ; Silbert, Lisa ; Erten-Lyons, Deniz ; Leverenz, James B. ; Bird, Thomas D. ; Pow, David V. ; Tanaka, Kohichi ; Watson, G. Stennis ; Cook, David G. / Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in alzheimer disease. In: Journal of Neuropathology and Experimental Neurology. 2010 ; Vol. 69, No. 7. pp. 667-676.
@article{00a1c5088e3f41edb22d44576773f9cf,
title = "Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in alzheimer disease",
abstract = "Alzheimer disease (AD) is characterized by deposition of amyloid-β, tau, and other specific proteins that accumulate in the brain in detergent-insoluble complexes. Alzheimer disease also involves glutamatergic neurotransmitter system disturbances. Excitatory amino acid transporter 2 (EAAT2) is the dominant glutamate transporter in cerebral cortex and hippocampus. We investigated whether accumulation of detergent-insoluble EAAT2 is related to cognitive impairment and neuropathologic changes in AD by quantifying detergent-insoluble EAAT2 levels in hippocampus and frontal cortex of cognitively normal patients, patients with clinical dementia rating of 0.5 (mildly impaired), and AD patients. Parkinson disease patients served as neurodegenerative disease controls. We found that Triton X-100-insoluble EAAT2 levels were significantly increased in patients withAD compared with controls, whereas Triton X-100-insoluble EAAT2 levels inpatients with clinical dementia rating of 0.5 were intermediately elevatedbetween control and AD subjects. Detergentinsolubility of presenilin-1, a structurally similar protein, did not differ among the groups, thus arguing that EAAT2 detergent insolubility was not causedby nonspecific cellular injury. These findings demonstrate that detergent-insoluble EAAT2 accumulation is a progressive biochemical lesion that correlates with cognitive impairment and neuropathologic changes in AD. These findings lend further support to the idea that dysregulationof the glutamatergic system may play a significant role in AD pathogenesis.",
keywords = "Alzheimer disease, EAAT2, Excitotoxicity, Glutamate, Mild cognitive impairment, Oxidative stress, Protein aggregation, SLC1A2",
author = "Woltjer, {Randall (Randy)} and Kevin Duerson and Fullmer, {Joseph M.} and Paramita Mookherjee and Ryan, {Allison M.} and Montine, {Thomas J.} and Jeffrey Kaye and Joseph Quinn and Lisa Silbert and Deniz Erten-Lyons and Leverenz, {James B.} and Bird, {Thomas D.} and Pow, {David V.} and Kohichi Tanaka and Watson, {G. Stennis} and Cook, {David G.}",
year = "2010",
month = "7",
doi = "10.1097/NEN.0b013e3181e24adb",
language = "English (US)",
volume = "69",
pages = "667--676",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in alzheimer disease

AU - Woltjer, Randall (Randy)

AU - Duerson, Kevin

AU - Fullmer, Joseph M.

AU - Mookherjee, Paramita

AU - Ryan, Allison M.

AU - Montine, Thomas J.

AU - Kaye, Jeffrey

AU - Quinn, Joseph

AU - Silbert, Lisa

AU - Erten-Lyons, Deniz

AU - Leverenz, James B.

AU - Bird, Thomas D.

AU - Pow, David V.

AU - Tanaka, Kohichi

AU - Watson, G. Stennis

AU - Cook, David G.

PY - 2010/7

Y1 - 2010/7

N2 - Alzheimer disease (AD) is characterized by deposition of amyloid-β, tau, and other specific proteins that accumulate in the brain in detergent-insoluble complexes. Alzheimer disease also involves glutamatergic neurotransmitter system disturbances. Excitatory amino acid transporter 2 (EAAT2) is the dominant glutamate transporter in cerebral cortex and hippocampus. We investigated whether accumulation of detergent-insoluble EAAT2 is related to cognitive impairment and neuropathologic changes in AD by quantifying detergent-insoluble EAAT2 levels in hippocampus and frontal cortex of cognitively normal patients, patients with clinical dementia rating of 0.5 (mildly impaired), and AD patients. Parkinson disease patients served as neurodegenerative disease controls. We found that Triton X-100-insoluble EAAT2 levels were significantly increased in patients withAD compared with controls, whereas Triton X-100-insoluble EAAT2 levels inpatients with clinical dementia rating of 0.5 were intermediately elevatedbetween control and AD subjects. Detergentinsolubility of presenilin-1, a structurally similar protein, did not differ among the groups, thus arguing that EAAT2 detergent insolubility was not causedby nonspecific cellular injury. These findings demonstrate that detergent-insoluble EAAT2 accumulation is a progressive biochemical lesion that correlates with cognitive impairment and neuropathologic changes in AD. These findings lend further support to the idea that dysregulationof the glutamatergic system may play a significant role in AD pathogenesis.

AB - Alzheimer disease (AD) is characterized by deposition of amyloid-β, tau, and other specific proteins that accumulate in the brain in detergent-insoluble complexes. Alzheimer disease also involves glutamatergic neurotransmitter system disturbances. Excitatory amino acid transporter 2 (EAAT2) is the dominant glutamate transporter in cerebral cortex and hippocampus. We investigated whether accumulation of detergent-insoluble EAAT2 is related to cognitive impairment and neuropathologic changes in AD by quantifying detergent-insoluble EAAT2 levels in hippocampus and frontal cortex of cognitively normal patients, patients with clinical dementia rating of 0.5 (mildly impaired), and AD patients. Parkinson disease patients served as neurodegenerative disease controls. We found that Triton X-100-insoluble EAAT2 levels were significantly increased in patients withAD compared with controls, whereas Triton X-100-insoluble EAAT2 levels inpatients with clinical dementia rating of 0.5 were intermediately elevatedbetween control and AD subjects. Detergentinsolubility of presenilin-1, a structurally similar protein, did not differ among the groups, thus arguing that EAAT2 detergent insolubility was not causedby nonspecific cellular injury. These findings demonstrate that detergent-insoluble EAAT2 accumulation is a progressive biochemical lesion that correlates with cognitive impairment and neuropathologic changes in AD. These findings lend further support to the idea that dysregulationof the glutamatergic system may play a significant role in AD pathogenesis.

KW - Alzheimer disease

KW - EAAT2

KW - Excitotoxicity

KW - Glutamate

KW - Mild cognitive impairment

KW - Oxidative stress

KW - Protein aggregation

KW - SLC1A2

UR - http://www.scopus.com/inward/record.url?scp=77954721991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954721991&partnerID=8YFLogxK

U2 - 10.1097/NEN.0b013e3181e24adb

DO - 10.1097/NEN.0b013e3181e24adb

M3 - Article

VL - 69

SP - 667

EP - 676

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 7

ER -